Mirati Therapeutics, Inc. (MRTX)
| Market Cap | 6.30B |
| Revenue (ttm) | 73.50M |
| Net Income (ttm) | -483.25M |
| Shares Out | 55.26M |
| EPS (ttm) | -9.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 586,750 |
| Open | 117.43 |
| Previous Close | 118.34 |
| Day's Range | 113.01 - 120.00 |
| 52-Week Range | 113.01 - 225.47 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | 220.08 (+93.0%) |
| Earnings Date | n/a |
About MRTX
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in precli...
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 220.08, which is an increase of 93.00% from the latest price.
News
Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in pretreated patients with pancreatic ductal adenocarci...
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated ...
SAN DIEGO, Jan. 21, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 stu...
Why Mirati Therapeutics Was Sinking This Week
A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual...
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 23, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference...
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutan...
SAN DIEGO and BOSTON, Nov. 22, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company c...
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration...
SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) app...
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $...
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC.
Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Stifel Healthcare Conference 2021, ...
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck & Co Inc's (NYSE: MRK) Keytr...
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
Mirati (MRTX) delivered earnings and revenue surprises of 45.99% and 91.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Nov. 8, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2021 and recent co...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such investors are advised t...
(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Mirati Therapeutics, Inc. (NASDAQ: MRTX) for violations of federal secu...
Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021
SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent cor...
Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology company, said its Chief Ope...
Earnings Preview: Mirati (MRTX) Q3 Earnings Expected to Decline
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inh...
SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi...
Biogen, Mirati and Arcturus Reportedly on Merck's Radar
Even after recently agreeing to shell out $11.5 billion to acquire Acceleron Pharma Inc. ( XLRN , Financial), Merck & Co. Inc. ( MRK , Financial) says it's not done in its quest for deals aimed at diver...
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal For $180/Share: Highlights.
Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual ...
SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at t...
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in connection with the hiring, announced on September...